Skip to content

The CArdiovasCulAr Diabetes & Ethanol (CASCADE) Trial

Cardiovascular and Metabolic Effects of Moderate Alcohol Consumption in Type 2 Diabetes

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00784433
Acronym
CASCADE
Enrollment
224
Registered
2008-11-04
Start date
2010-06-30
Completion date
2012-05-31
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Prediabetes

Keywords

alcohol diabetes CVD

Brief summary

Moderate alcohol may be beneficial for diabetics

Interventions

DIETARY_SUPPLEMENTalcohol

150 cc

Sponsors

Ben-Gurion University of the Negev
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Established diagnosis of type 2 diabetes * Male or female alcohol abstainers (not more than 1 drink/week) * Age between 40-75 yrs * Clinically stable, with no history of stroke or myocardial infarction or major surgery within the previous 3 months

Exclusion criteria

* The use of RI or short-acting analog insulin/ pump therapy. Patients on 1-2 injections per day of NPH or long-acting analogs will be eligible for inclusion * Triglycerides \> 500 mg/dL * HbA1c\<7 or \> 10% * Serum creatinine \> 2 mg/dl * Liver dysfunction (greater than 2-fold elevation of ALT or and 3-fold elevation of AST) * Evidence of severe diabetes complications (such as proliferative retinopathy or overt nephropathy) * Autonomic neuropathy manifested as postural hypotension or hypoglycemia unawareness * Patients with chronic hepatitis (C,B) * Use of drugs that might significantly interact with alcohol such as sedatives, antihistamines, and anti-coagulants * Presence of active cancer, or chemotherapy within the past 3 years * Major illness that may require hospitalization * A high potential of addictive behavior based on physician's assessment or personal or family history of addiction, alcoholism, or alcohol abuse * Pregnant or lactating woman * Participation in another trial with active intervention

Design outcomes

Primary

MeasureTime frame
Glycemic control6 months

Secondary

MeasureTime frame
CVD status6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026